Supernus Pharmaceuticals Inc (SUPN)
NASDAQ
News
Market Data
Customized watchlists with full streaming quotes from leading exchanges, such as NASDAQ, NYSE, AMEX, OTC Markets Small-Cap, LSE and more.
The current SUPN market cap is 1.75B. The company's latest EPS is USD 0.0239 and P/E is 1331.38.
| Quarter End | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Revenue | 134.77M | 154.34M | 164.52M | 144.74M | 172.68M |
| Operating Income | -17.59M | 8.14M | -996k | -3.15M | 22.57M |
| Net Income | -831k | -15.98M | 1.18M | 124k | 19.92M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Revenue | 392.76M | 520.4M | 586.31M | 667.75M | 609.04M |
| Operating Income | 148.57M | 173.7M | 86.03M | 46.12M | -5.27M |
| Net Income | 113.06M | 126.95M | 53.42M | 60.71M | 1.32M |
| Quarter End | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Assets | 1.29B | 1.29B | 1.28B | 1.3B | 1.32B |
| Total Liabilities | 373.19M | 372.97M | 356.16M | 374.92M | 358.38M |
| Total Equity | 919.91M | 912.19M | 921.52M | 929.17M | 957.45M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Assets | 1.16B | 1.5B | 1.69B | 1.7B | 1.28B |
| Total Liabilities | 564.85M | 759.24M | 873.3M | 816.3M | 356.16M |
| Total Equity | 595.43M | 744.86M | 815.85M | 886.2M | 921.52M |
| Quarter End | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Operating | 30.25M | 66.13M | 111.09M | 38.4M | 74.03M |
| Investing | 300.08M | 334.71M | 268.73M | -51.62M | -100.22M |
| Financing | -398.74M | -398.97M | -397.88M | 1.57M | 3.23M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Operating | 143.13M | 138.4M | 127.13M | 116.83M | 111.09M |
| Investing | -157.92M | -34.7M | -81.91M | -216.66M | 268.73M |
| Financing | 3.93M | 3.56M | -130.42M | -10.48M | -397.88M |
| Market Cap | 1.75B |
| Price to Earnings Ratio | 1331.38 |
| Price to Sales Ratio | 2.88 |
| Price to Cash Ratio | 23.36 |
| Price to Book Ratio | 1.9 |
| Dividend Yield | - |
| Shares Outstanding | 55.11M |
| Average Volume (1 week) | 474.1k |
| Average Volume (1 Month) | 389.56k |
| 52 Week Change | 13.20% |
| 52 Week High | 35.44 |
| 52 Week Low | 21.99 |
| Spread (Intraday) | 1.62 (5.09%) |
| Company Name | Supernus Pharmaceuticals Inc |
| Address |
1209 orange street wilmington, delaware 19801 |
| Website | https://www.supernus.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
